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Abstract
Background and Purpose: In 2007, the WHO classification of brain tumors was extended by three new entities of
glioneuronal tumors: papillary glioneuronal tumor (PGNT), rosette-forming glioneuronal tumor of the fourth ventricle
(RGNT) and glioneuronal tumor with neuropil-like islands (GNTNI). Focusing on clinical characteristics and outcome, the
authors performed a comprehensive individual patient data (IPD) meta-analysis of the cases reported in literature until
December 2012.
Methods: PubMed, Embase and Web of Science were searched for peer-reviewed articles reporting on PGNT, RGNT, and
GNTNI using predefined keywords.
Results: 95 publications reported on 182 patients (PGNT, 71; GNTNI, 26; RGNT, 85). Median age at diagnosis was 23 years
(range 4–75) for PGNT, 27 years (range 6–79) for RGNT, and 40 years (range 2–65) for GNTNI. Ninety-seven percent of PGNT
and 69% of GNTNI were located in the supratentorial region, 23% of GNTNI were in the spinal cord, and 80% of RGNT were
localized in the posterior fossa. Complete resection was reported in 52 PGNT (73%), 36 RGNT (42%), and 7 GNTNI (27%)
patients. Eight PGNT, 3 RGNT, and 12 GNTNI patients were treated with chemo- and/or radiotherapy as the primary
postoperative treatment. Follow-up data were available for 132 cases. After a median follow-up time of 1.5 years (range 0.2–
25) across all patients, 1.5-year progression-free survival rates were 52612% for GNTNI, 8665% for PGNT, and 100% for
RGNT. The 1.5-year overall-survival were 9565%, 9862%, and 100%, respectively.
Conclusions: The clinical understanding of the three new entities of glioneuronal tumors, PGNT, RGNT and GNTNI, is
currently emerging. The present meta-analysis will hopefully contribute to a delineation of their diagnostic, therapeutic, and
prognostic profiles. However, the available data do not provide a solid basis to define the optimum treatment approach.
Hence, a central register should be established.
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Background
In the most recent update of the World Health Organization
(WHO) classification of central nervous system (CNS) tumors
[29,30], three new entities have been added to the repertoire of
glioneuronal tumors: papillary glioneuronal tumor (PGNT) (WHO
grade I), rosette-forming glioneuronal tumor of the fourth ventricle
(RGNT) (WHO grade I), and rosetted glioneuronal tumor with
neuropil-like islands (GNTNI) (WHO grade II/III) [29,40].
PGNT, a mixed tumor consisting of glial und neuronal histological
differentiation, shows a typical structure of GFAP-positive
psedopapillae surrounded by an interpapillary (neuronal) zone
[2]. Necroses and elevated mitotic activities are rarely seen [3].
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The biphasic histopathology, consisting of neurocytic and glial
architecture, is also typical for RGNT [29,30]. Neurocytes of the
neuronal component shape rosettes with eosinophilic, synapto-
physin-positive cores and perivascular pseudorosettes. The glial
part of the tumor, showing similar features like pilocytic
astrocytoma, represents the larger portion [39]. In contrast,
GNTNI shows features of a high-grade glioma, mostly interpreted
as astrocytic [43], but ependymal or oligodendroglial differentia-
tion is possible [12]. Dispersed in this glial component, the most
prominent feature of these tumors, rosetted neuropil-like islands,
can be found [37].
Although morphological, immunohistochemical, and molecular
features have been intensively investigated over recent years
[29,30], clinical features, current treatment approaches, and
prognosis are still elusive. The pertinent literature on the topic is
primarily limited to single- case reports or small case series and do
not provide a comprehensive overview. In 2009, Allende et al.
aimed to summarize the pathological and clinical findings of
PGNT, RGNT, and GNTNI [3]. However, a major methodo-
logical shortcoming of their review is based on the fact that a
systematic literature search was not performed. Accordingly, their
findings may be biased by the authors’ personal opinions or the
selection of publications included in their analysis. In particular,
the variety of articles published during the past four years may
contribute valuable new information toward the understanding of
the three previously mentioned entities. The purpose of this
individual patient data meta-analysis was to increase the current
knowledge about clinical features, treatment, and outcome of
PGNT, RGNT and GNTNI.
Materials and Methods
Scientific question
The purpose of the present IPD meta-analysis was to assess the
clinical characteristics and outcome of the patients with PGNT,
RGNT and GNTNI reported in the literature.
Search strategy and selection criteria
The authors searched PubMed, Embase and Web of Science
from January 1998 to December 2012 (the last update to all
databases was on December, 17, 2012) for published articles with
predefined search terms without language restrictions. The search
was assisted by an experienced librarian (Mrs. Christiane
Hofmann; library of the University of Leipzig). The keywords
were (1) (papillary) AND (glioneuronal OR glioneural) AND
(tumor OR tumour OR neoplasm), (2) (rosette forming OR
rosetted) AND (glioneuronal OR glioneural) AND (tumor OR
tumour OR neoplasm), (3) neuronal AND (glioneuronal OR
glioneural) AND (tumor OR tumour OR neoplasm); (1) OR (2)
OR (3). The process of publication retrieval and in- and exclusion
of cases is displayed in a PRISMA (preferred reporting itmens for
systematic review and meta-analysis) flow chart [34] (Fig. 1).
Figure 1. Systematic literature search. Procedure of publication retrieval and in- and exclusion of cases is displayed in a PRISMA (preferred
reporting items for systematic reviews and meta-analyses) flow chart.
doi:10.1371/journal.pone.0101211.g001
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of casesa Abstract y/n
Language
of abstract Information delivered
1 Polish n/s n/s no n/s –
2 Chinese yes 1 no n/s –
3 Russian yes 1 yes English histology, age+gender of patient, tumor location, no symptoms/
treatment/PFS/OS
4 Chinese yes 1 no n/s –
5 Chinese yes 1 yes English age+gender of patient, symptoms, MRI-character (solid/cystic), tumor
location, histology, treatment, follow-up
6 Chinese yes 2 no n/s –
7 Chinese yes 2 no n/s –
8 Japanese no 0 yes English WHO classification 2007
9 Slovakian no 0 yes English WHO classification 2007
Note: n/s – not specified; y/n – yes/no.
aProvided by title of the article or abstract if available.
doi:10.1371/journal.pone.0101211.t001
Figure 2. Number of published case reports. There is an increasing number of case reports over the last years.
doi:10.1371/journal.pone.0101211.g002
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The authors identified 267 hits from a search of PubMed,
Embase, and Web of Science databases. These were imported in
reference management software (endnote.com X6.0.1). Titles and
abstracts were reviewed by one researcher (AS). Duplications were
excluded (n = 15). In addition to the obvious duplicates (e.g. same
articles twice), we identified identical cases by reviewing investi-
gators in the study and patient characteristics. Results obtained on
the same cohort of cases in multiple publications were collected
only once, similar as described in a previos study [32], by including
the largest series of patients.
Furthermore the authors excluded 101 abstracts because the
subjects were not related to the aforementioned search terms.
Case- series or cohort studies reporting on papillary glioneuronal
tumor (PGNT) (WHO grade I), rosette-forming glioneuronal
tumor of the fourth ventricle (RGNT) (WHO grade I), and
rosetted glioneuronal tumor with neuropil-like islands (GNTNI)
(WHO grade II/III) were included.
Another 16 meeting abstracts were excluded as well as five
abstracts with insufficient data for which no full-text was available
despite interlibrary loan. One exception was made, including one
abstract providing sufficient information about one case without
the available full-text.
Nine non-English articles in Polish, Chinese, Russian, Japanese
and Slovakian were found. For eight of these nine articles, no full-
texts were available; however there was one article with an English
abstract and available Chinese full-text. For inclusion, the authors
translated this article and contacted the authors of the study to
receive sufficient data for the meta-analysis. For three articles the
English abstracts were disposable, of which two were reviews and
did not include original data. Those two reviews were therefore
excluded. The remaining abstract (case report) was included,
despite limited data. To complete the limited data we contacted
the authors of the study, but no responses were received in time.
The remaining five articles were excluded because neither the full-
texts nor the abstract were available (Table 1).
Overall, the authors assessed 123 eligible articles, 121 full-texts,
and 2 abstracts. Possible additional studies were traced by
checking the reference lists of selected publications, but they did
not provide any further articles. Papers were reviewed by two
authors (AS and AOvB). Disagreements were resolved through
discussion and consensus with a third author (CH and/or KM). In
case of uncertainty with regard to histopathological diagnosis, CH
assessed whether diagnoses were based on mandatory analysis for
the 2007 WHO classification of tumors of the central nervous
system: Data from five patients whose tumor could not be
histologically categorized according to the 2007 WHO grading
system were excluded (part of the 28 excluded full-texts). The
following criteria were used: (1) published immunohistochemistry,
(2) growth pattern as described by WHO 2007 classification, and
(3) case report considered as typical example by authors.
Data collection, quality control, and data synthesis
Information on the symptoms at diagnosis, histopathological
diagnoses, patient characteristics, MRI findings, treatments, and
outcomes were recorded on a standard data extraction form.
To ensure correct histopathological diagnosis according to the
criteria defined by the 2007 WHO classification of tumors of the
central nervous system, articles published before 2007 were
Figure 3. Kaplan-Meier Plot PFS.
doi:10.1371/journal.pone.0101211.g003
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included only if they were cited in the 2007 WHO classification of
tumors of the central nervous system (‘‘blue book’’) or after a
detailed assessment of the description of the analysis was
performed to diagnose a case by an experienced neuropathologist
(CH) in order to check whether criteria to diagnose a case
according to the 2007 WHO classification of tumors of the central
nervous system are fulfilled.
Any obvious errors (plausibility tests), inconsistencies with
publication, inconsistencies between variables, or extreme values
were discussed with the authors (CH and KM) and corrected
where necessary.
Statistics
Study- level data were collected (95 studies; 182 patients).
Because of the small number of patients per study, the study-level
characteristics are not presented for each individual case report or
case series. A one-stage approach according to Simmonds et al.
was used to pool all data into a single master database [44].
PFS was defined, as described elsewhere [18], as the time from
date of diagnosis to first progression or relapse or tumor-related
death. Last contact (without an observed event) or death unrelated
to progression or relapse required censoring.
For overall survival (OS) death by any cause was taken into
account. Survival times were calculated from the date of diagnosis
onwards. The Kaplan–Meier method was used to estimate PFS
and OS rates. PFS estimates were compared by means of the log
rank test. In some cases the date of diagnosis differed from the date
of surgery. Therefore, the influence of the extent of resection on
the PFS was not assessed. In addition to the assessment by means
of the Kaplan-Meier method and the log rank test, each variable
was tested individually in a Cox proportional hazards model using
the change in log likelihood from the null model. All analyses are
exploratory; therefore, no significance level was fixed. All analyses
were performed using SPSS, version 20 (SPSS Inc., Chicago, IL,
USA).
Ethical standards
This manuscript is in accordance with the ethical standards
established in the 1964 Declaration of Helsinki and its subsequent
amendments.
Results
The authors evaluated the full text articles of 95 publications
reporting on 182 patients with PGNT (n = 71), RGNT (n = 85),
and GNTNI (n = 26) (Fig. 2). A detailed description of references
containing patient data is provided in File S1.
Clinical characteristics and first-line treatment
PGNT. In total, we assessed 71 patients with PGNT. Thirty-
three (46.5%) were male. Median age at diagnosis was 23 years
(range, 4–75 years). The majority of PGNT (97.2%) were located
in the supratentorial region. Primary metastatic dissemination was
evident in one case (Table 2). In 64 out of 71 patients (90.1%)
diagnosis was preceded by neurological symptoms, most frequently
headache, seizures, and nausea/vomiting (Table 3). Complete
resection was reported in 52 cases. Two patients received adjuvant
radiation therapy after complete tumor resection (1x focal RT with
Figure 4. Kaplan-Meier Plot OS.
doi:10.1371/journal.pone.0101211.g004
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55 Gy, 1x no RT details available). Six patients with incomplete
tumor resection underwent adjuvant radiotherapy (n = 2),
chemotherapy (n = 1), or both (n = 3). RT details were not
reported except in one case (focal RT with 45 Gy). The outcome
was reported in 57 out of 71 patients. Ten patients progressed and
two patients died. The median follow-up time of surviving patients
was 1.5 years (0.2–19.0 years) (Table 2). The 1.5-year PFS and OS
rates were 86% 65% and 98% 62% (2-year PFS were 82% 66%
and OS 98% 62%, respectively) (Figs. 3 and 4).
RGNT. The authors evaluated 85 patients [men, 39 (45.9%)]
with RGNT. The median age at diagnosis was 27 years (range, 6–
79 years). Eighty percent of the tumors were located in the
infratentorial region. Six patients presented with primary meta-
static spread (Table 2). In 58 out of 85 cases (68.2%) the diagnosis
was preceded by neurological symptoms, most frequently head-
ache, abnormalities of gait and coordination, and nausea and
vomiting (Table 3). Complete resection was achieved in at least 36
cases. Three patients with incomplete tumor resection received
focal RT (total doses 46, 55, and 57 Gy, respectively). The
Table 2. Clinical Characteristics of ….
PGNT (n = 71) RGNT (n = 85) GNTNI (n = 26)
Characteristics n % n % n %
Gender
Male 33/71 46.5 39/85 45.9 17/26 65.4
Female 38/71 53.5 46/85 54.1 9/26 34.6
Age at diagnosis
Median (range) 23.0 years (4.0–75.0 years) 27.0 years (6.0–79.0 years) 40.0 years (2.0–65.0 years)
Children (,18 years) 25/71 35.2 18/85 21.2 6/26 23.1
Adults ($18 years) 46/71 64.8 67/85 78.8 20/26 76.9
Patients ,26 years 42/71 59.2 40/85 47.1 8/26 30.8
Patients $26 years 29/71 40.8 45/85 52.9 18/26 69.2
Tumor location
supratentorial 69/71 97.2 13/85 15.3 18/26 69.2
Posterior fossa 1/71 1.4 68/85 80.0 – –
Spinal – – 1/85 1.2 6/26 23.1
More than one area 1/71 1.4 3/85 3.5 2/26 7.7
Primary metastasis 1/71 1.4 6/85 7.1 4/26 15.4
Proliferation index (Ki-67)
Ki-67 reported 55/71 77.5 64/85 75.3 24/26 92.3
Median (range) (%) 1.8 (0.5–50.0) 1.0 (0.4–4.9) 4.0 (1.0–20.0)
.1.6% 27/55 49.1 18/64 28.1 21/24 87.5
#1.6% 28/55 50.9 46/64 71.9 3/24 12.5
Tumor size (cm), reported 51/71 71.8 36/85 42.4 5/26 19.2
median (range) 4.0 (1.0–9.0) 3.0 (0.5–9.6) 4.5 (3.5–6.0)
.3.5 cm 30/51 58.8 8/36 22.2 3/5 60.0
#3.5 cm 21/51 41.2 28/36 77.8 2/5 40.0
Character in imaging, reported 61/71 85.9 51/85 60.0 26/26 100.0
solid 5/61 8.2 19/51 37.3 19/26 73.1
cystic parts 56/59 91.8 32/51 62.7 7/26 26.9
Extent of tumor resection
Complete resection 52/65 80.0 36/63 57.1 7/25 28.0
Incomplete resection 13/65 20.0 27/63 42.9 18/25 72.0
Not reported 6/71 8.5 22/85 25.9 1/26 3.8
Follow-up time of survivors
Median (range) 1.5 years (0.2–19.0 years) 1.2 years (0.2–13.5 years) 1.7 years (0.6–7.0 years)
Outcome
Assessable for PFS 57/71 80.3 52/85 61.2 21/26 80.8
Disease progressions 10/57 17.5 4/52 7.7 14/21 66.7
Assessable for OS 57/71 80.3 52/85 61.2 23/26 88.5
Deaths 2/57 3.5 3/52 5.8 3/23 13.0
doi:10.1371/journal.pone.0101211.t002
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outcome was reported in 52 out of 85 patients (61.2%). Four
patients progressed and three patients died. The median follow-up
time of surviving patients was 1.2 years (0.2–13.5 years) (Table 2).
The PFS and OS rates at 1.5 and 2 years after diagnosis were
100%, respectively (Figs. 3 and 4).
GNTNI. Twenty-six patients with GNTNI were investigated.
Seventeen (65.4%) were male. The median age at diagnosis was 40
years (range, 2–65 years).
Tumors were in the supratentorial (69.2%) and spinal (23.1%)
regions. Four patients showed initial metastases (Table 2). All
patients were symptomatic when diagnosed with seizures and
headache being the most frequent clinical signs (Table 3). Gross
total resection was not achievable in 18 out of 26 patients. Ten
with incomplete (n = 9) or unknown extent of tumor resection (n
= 1) underwent adjuvant focal radiotherapy (n = 4), irradiation of
the craniospinal axis (n = 1, disseminated disease), or focal
radiotherapy and chemotherapy (n = 5). The maximum RT doses
were reported in five cases (2 6 60 Gy, 50 Gy, 59.4 Gy, and
50.4 Gy). Two patients underwent adjuvant treatment (chemo-
therapy, n = 1; RT and chemotherapy, n = 1) despite complete
tumor resection. The outcome was reported in 21 patients.
Fourteen patients progressed and three patients died. The median
follow-up time of surviving patients was 1.7 years (0.6–7.0 years)
(Table 2). Progression-free and overall survival rates at 1.5 years
after diagnosis were 52% 612% and 95% 65%, respectively
(Figs. 3 and 4). Two-year PFS was 44% 612% and OS 95%
65%.
Evaluation of potential prognostic factors for PFS across
all three entities
Univariable analyses, Kaplan-Meier method and log rank
test. Neither gender (p = 0.315) nor age (cut-off of 18 years; p
= 0.846; cut-off of 26 years as median age for all patients: p
= 0.575) had an on PFS. In contrast, univariable survival analyses
identified histology (p,0.001), WHO grading (p,0.001), the Ki-
67 proliferation index (cut-offs of 1.6 and 5.0%, respectively)
(1.6%, p = 0.002; 5.0%, p,0.001), the maximum tumor diameter
as measured on imaging [cut-off 3.5 cm (median size of tumor) (p
= 0.028)], and the occurrence of cystic tumor parts (p = 0.015) as
critical factors for PFS. Patients with primary metastatic disease
tended to progress earlier (p = 0.054) (Fig. 3, Table 4).
Cox proportional hazards regression analysis
(continuous variables). In the univariable cox regression
analysis age (p = 0.128, hazard ratio = 1.02 per year, 95% CI:
0.99–1.04) and the maximum tumor diameter (p = 0.057, hazard
ratio = 1.338 per cm, 95% CI: 0.992–1.805) did not influence
PFS, whereas the proliferation index of Ki-67 (p = 0.003, hazard
ratio = 1.10 per %, 95% CI: 1.03–1.18) did.. As an example, a 1%
increase in Ki-67 positive tumor cells extended the risk of
progression by 10% and a 10% increase in Ki-67 positive tumor
cells by 259% (1.110). For the categorical variables (WHO grading,
gender, primary metastasis and the occurrence of cystic tumor
parts), the results delivered by the Kaplan-Meier method and the
log rank test were confirmed (Table 5).
Table 3. Initial symptoms and radiology features.
PGNT (n = 71) RGNT (n = 85) GNTNI (n = 26)
Characteristics n % n % n %
Information about initial symptoms provided 66/71 93.0 66/85 77.6 26/26 100.0
symptomatic 64/66 97.0 58/66 87.9 26/26 100.0
headache 39/64 60.9 43/58 74.1 3/26 11.5
nausea/vomiting 15/64 23.4 15/58 25.9 2/26 7.7
abnormality of gait and coordination 3/64 4.7 18/58 31.0 2/26 7.7
papilloedema or optic atrophy 8/64 12.5 6/58 10.3 0/26 0.0
seizures 21/64 32.8 2/58 3.4 17/26 65.4
visual disturbance 12/64 18.8 9/58 15.5 0/26 0.0
Radiology
Character in imaging, reported 61/71 85.9 51/85 60.0 26/26 100.0
solid 5/71 7.0 19/51 37.3 19/26 73.1
cystic 8/61 13.1 11/51 21.6 0/26 0.0
cystic with mural nodule 23/61 37.7 0/51 0.0 5/26 19.2
cystic and solid 25/61 41.0 21/51 41.2 2/26 7.7
enhancement, reported 63/71 88.7 61/85 71.8 26/26 100.0
enhancement 60/63 95.2 44/61 72.1 14/26 53.8
density in MR-imaging T1 44/71 62.0 52/85 61.2 12/26 46.2
hypointens 41/44 93.2 48/52 92.3 11/12 91.7
hyperintens 3/44 6.8 – – 1/12 8.3
isointens – – 4/52 7.7 – –
density in MR-imaging T2 39/71 54.9 47/85 55.3 12/26 46.2
hypointens 0/39 0.0 – – 1/12 8.3
hyperintens 39/39 100.0 40/47 85.1 11/12 91.7
isointens – – 7/47 14.9 – –
doi:10.1371/journal.pone.0101211.t003
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Discussion
General aspects
PGNT, RGNT, and GNTNI have been raising more and more
awareness in (clinical) neuro-oncology over recent years. This was
particularly underscored by the special recognition given to them
in the latest update of the WHO classification of CNS tumors
[29,30,40]. Meanwhile, a considerable number of case reports and
small case series have been published (Fig. 2). Now, studies
extracting and subsequently interpreting the available data are
highly needed. Recently, Zhang et al. assessed a total of 41 RGNT
patients reported in the literature between 2002 and 2012 [52].
However, comparable studies for PGNT and GNTNI do not exist
so far to the best of our knowledge. The aim of the present study is
to provide a comprehensive meta-analysis for all three entities.
Through a systematic literature search, we were able to generate a
data set containing 71 cases of PGNT, 85 cases of RGNT, and 26
cases of GNTNI.
PGNT
PGNT is a rare tumor of the central nervous system, first
described by Komori et al. in 1998 [24]. Histopathological
features, including biphasic components of glial and neuronal
pattern as well as radiological characteristics such as frequent
occurrence of a cystic lesion with mural nodule (39%, Table 3) or
Table 4. Impact of potential prognostic factors on progression.
Factor n = 2-year PFS (%) 1.5-year PFS (%) p =
Histology
Assessable for PFS 130/180 (71.4%)
PGNT 57/130 (43.8%) 8266 8665 0.000
RGNT 52/130 (40.0%) 100 100
GNTNI 21/129 (16.2%) 44612 52612
WHO Grade
Assessable for PFS 130/182 (71.4%)
WHO uI 109/130 (83.8%) 9064 9363 0.000
WHO u II/III 21/130 (16.2%) 44612 52612
Gender
Assessable for PFS 130/182 (71.4%)
Male 62/130 (47.7%) 7967 8665 0.315
Female 68/130 (52.3%) 8265 8265
Age
Accessible for PFS 130/182 (71.4%)
Children (,18 years) 39/130 (30.0%) 7768 8367 0.846
Adults ($18 years) 91/130 (70,0%) 8265 8564
Patients ,26 years 68/130 (52.3%) 8366 8665 0.575
Patients $26 years 62/130 (47.7%) 7867 8266
Primary metastasis
Accessible for PFS 130/182 (71.4%)
yes 9/130 (6.9%) 51620 51620 0.054
no 121/130 (93.1%) 8364 8764
Proliferation index (Ki-67) (%)
Accessible for PFS 111/182 (61.0%)
.1.6 50/111 (45.0%) 9265 9265 0.002
#1.6 61/111 (55.0%) 6668 7367
$5 93/111 (83.8%) 44613 53612 0.000
,5 18/111 (16.2%) 8865 9064
Maximum tumor diameter (cm)
Accessible for PFS 73/182 (40.1%)
.3.5 36/73 (49.3%) 8167 8167 0.028
#3.5 37/73 (50.7%) 9763 9763
Appearance on imaging 137/182 (75.3%)
Accessible for PFS 113/182 (62.1%)
Exclusively solid 31/113 (27.4%) 68611 7669 0.015
cystic parts 82/113 (72.6%) 8565 8764
doi:10.1371/journal.pone.0101211.t004
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mixed solid-cystic lesions (39%, Table 3) with ring-like enhance-
ment in MRI, are able to facilitate the diagnosis [9,50]. However,
the differentiation among ganglioglioma, pleomorphic xanthoas-
trocytoma, pilocytic astrocytoma and dysembryoplastic neuroep-
ithelial tumor can sometimes be challenging [7,39,49].
When defined as a WHO grade I tumor, a benign course and
an excellent prognosis can be assumed, especially when presenting
with a low proliferation index or after gross total tumor resection
(GTR). This study’s PGNT showed a 1.5-year PFS of 86% 65%
and a 1.5-year OS of 98% 62%, respectively (Figs. 3 and 4). Even
cases with an elevated proliferation index showed a favorable
course [6,10,20,22,23,35]. As a single exception to the rule one
case of PGNT recurred despite GTR and low proliferation [23].
Therefore, no certain correlation between outcome and the extent
of the tumor resection or the proliferation index can be made,
which might give the impression that genetic alterations of PGNT
may be a key issue for our understanding [28].
PGNT mostly occurs in young adults, but with a wide range in
age (median age 23.0 years, Table 2). Initial symptoms can be seen
in almost every case (64/71 patients, 90%, Table 3), resulting in
physical examination and diagnostic services such as CT or MRI.
At the time of diagnosis, a median tumor size of 4.0 cm (range
1.0–9.0) was shown in radiological imaging. In most cases
enhancement of the tumor was reported (60/71 patients, 85%,
Table 3), in addition to hyperintensity in T2-MR imaging
(Table 3).
Most patients (80%, Table 2) received GTR and had an
excellent prognosis, indicating that this is the first-choice treatment
for PGNT [10,11,13,27,38]. Any additional therapy such as
radiotherapy or chemotherapy appears to be necessary only in a
minority of patients. Whether adjuvant treatment was adminis-
tered for PGNT patients was reported in 31 (chemotherapy) and
35 (radiotherapy) out of 71 cases (45 and 49%, respectively). Four
patients received chemotherapy (6% of all cases), all after STR,
and seven patients got radiotherapy (10% of all cases; five after
STR, two after GTR). However, there might be the possibility that
more patients received adjuvant therapy than the authors are
aware because of the low rate of reported data. Possible reasons for
adjuvant treatment include high proliferation index, inoperability
and progressive disease [16,47]. Regular radiological monitoring is
necessary to detect any recurrence of tumor. In this case, surgical
intervention should be considered first [8].
RGNT
First described as dysembryoplastic neuroepithelial tumor
(DNT) of the cerebellum by Kuchelmeister et al. in 1995 [26],
Komori et al. defined RGNT as a specific disease in 2002 [25].
RGNT is a rare tumor of the central nervous system, typically
arising in the III and IV ventricles. An increasing number of
patients are now known with RGNT outside the characteristic
location, such as in the pineal region, optic chiasm, spinal cord and
septum pellucidum [5,19,42,45,51]. Radiologically, a solid or
mixed solid/cystic tumor can be found in 37 and 41%,
respectively, usually enhancing (72% of 61 reported cases), with
hyper-intense signals in T2-MRI (85%) and iso- or hypo- intense
signals in T1-MRI (92%, Table 3) [52]. Similar to PGNT, RGNT
histologically consists of both glial and neuronal components [43].
Pseudorosettes are the most characteristic feature. Against the
background of a histological similarity to DNT, some publications
discussed that RGNT might be the infratentorial version of
cerebral DNT [25,26]. Differential diagnoses include pilocytic
astrocytoma, ependymoma, oligodendroglioma, central neurocy-
toma and DNT, of course [43,51]. Thus, a distinct diagnosis might
be demanding.
Occurring primarily in young adulthood (median age 27.0
years), one case of a 79-year-old patient provides some evidence
that this tumor may also occur in older persons [31].
Classified as a WHO grade I tumor, RGNT is characterized by
a favorable prognosis upon surgical resection: a 1.5-year PFS and
OS of 100% was achieved in RGNT patients in this study’s data
set (Figs. 3 and 4). However, local recurrences have been reported
as well as disseminated disease in 7% (Table 2) [15,48], leading to
the hypothesis that GTR is the treatment of first choice. As far as
the authors are aware, only about half of the patients received
GTR, leaving many cases with subtotal resection (STR) (Table 2).
Some authors even recommended performing a biopsy only
[25,48]. Zhang et al. (2013) could not show any difference in
Table 5. Cox Regression.
Factor p = hazard ratio (HR) 95% confidence interval (HR)
WHO Grade
uI
uII/III 0.000 0.137 0.062–0.305
Gender
Male 0.320 0.675 0.312–1.463
Female
Age 0.128 1.017 0.995–1.039
Primary metastasis
yes
no 0.069 0.316 0.091–1.095
Proliferation index (Ki-67) (%) 0.003 1.102 1.033–1.175
Maximum tumor diameter (cm) 0.057 1.338 0.992–1.805
Appearance on imaging
Exclusively solid 0.020 2.659 1.168–6.052
Cystic parts
doi:10.1371/journal.pone.0101211.t005
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survival when comparing patients with GTR versus STR [52],
which might be the result of the small number of cases.
Even though it is challenging because of the delicate tumor
location, surgery seems to remain the most important first-line
therapy, whereas radiotherapy should be considered as adjuvant
treatment for progressive or disseminated diseases as well as
definitive treatment in case of inoperability [25,48,52]. Data about
given adjuvant treatment for RGNT was reported in 76% of this
study’s cases: Three patients received radiotherapy, which is 4% of
all cases (all after STR), but no chemotherapy was given (data not
shown). The robustness of this information might be slightly
limited because of the possibility that more patients may have
received chemotherapy and/or radiotherapy.
GNTNI
In 1999, Teo et al. described GNTNI as a scarce tumor that
differs from PGNT and RGNT [46]. Characterized as a WHO
grade II or III tumor, it is the only one of these three entities that is
not part of the glioneuronal tumor category [3]; instead, it is
categorized as astrocytoma [29,30]. GNTNI appears with a
biphasic histology consisting of neurocytic cells that surround
distinctive oval neuropil-rich islands and fibrillary, protoplasmic,
or gemistocytic astrocytes as part of the glial component [1,2,41].
This glial part exposes anaplastic features such as increased
cellularity, frequent mitosis and necrosis, nuclear pleomorphism,
high proliferation index, and/or microvascular proliferation. In
this study’s analysis, GNTNI showed a median proliferation index
of 4.0% (range 1.0–20.0%), compared with a median proliferation
index of 1.6% for PGNT and 1.0% for RGNT (Table 2). This
might help to differentiate this tumor from both PGNT and
RGNT. Differential diagnoses include ependymomas (with
neuropil-like islands), oligodendrogliomas (with neurocytic differ-
entiation), or RGNT.
Most of these tumors are located in the supratentorial region
(69%); however, spinal (23%) and even disseminated disease at
primary diagnosis (8%) have been described by authors frequently
(Table 2) [17,21,37,41]. Showing variable contrast enhancement
(Table 3), GNTNIs appear mostly as solid tumor in 73%, or, a
smaller amount of 19%, cystic with a mural nodule with T2-
hyperintensity (92%) and T1-hypointensity (92%) (Table 3) [4].
GNTNI shows an unfavorable prognosis when compared with
RGNT and PGNT (1.5-year PFS 52% 612%, 1.5-year OS 95%
65%; Figs. 3 and 4), which is reflected in the histomorphology and
the grading. Most of all published cases have been treated with
incomplete resection (72%, Table 2). Again, this increases the risk
of local recurrence. The best therapy for patients with GNTNI
remains a serious challenge. Radiotherapy and chemotherapy as
adjuvant treatments after resection are important and constitute a
cornerstone of the treatment that should be discussed for every
patient. A total of 21 out of 26 (81%) cases reported about
adjuvant treatment: seven patients received chemotherapy (27% of
all cases) and 11 patients radiotherapy (42% of all cases) (data not
shown). Most patients received adjuvant treatment after an
incomplete resection of the tumor (10/11 radiotherapy and 5/7
chemotherapy). For disseminated disease, a definitive radiotherapy
or radiochemotherapy is conceivable but must be considered as an
experimental approach. Even though much remains uncertain,
treatment of GNTNI may include the cornerstones of the
treatment of diffuse astrocytoma, because of the histopathological
similarity.
Limitations of this study
To the author’s knowledge, we generate the first analysis
containing progression-free and overall-survival for these three
entities. It turns out that PGNT, RGNT and GNTNI demonstrate
good survival rates. However, the authors cannot fully eliminate
several limitations of the study.
First, the follow-up period is too short to draw definitive
conclusions. Therefore, a registry study is needed for these rare
tumors to collect follow-up data over a longer period.
Second, without a doubt, the patients in this study underwent
very heterogeneous treatments. This may bias outcome and
prognosis.
Third, unfortunately the authors failed to find every single full-
texts for every abstract or hit, especially for the non-English case
studies. Thus, two of the 95 case- series or cohort studies were
assessed by abstracts only, and seven non-English hits were
excluded entirely, resulting in another limitation of this study.
Statistical limitations
On univariate analyses the authors identified a variety of
potential risk factors for PFS (Fig. 3, Table 3). However, it is highly
improbable that all these factors are independent of each other.
The simultaneous s of several variables on survival times are
usually investigated by means of the Cox proportional hazard
regression model. However, for the results to be reliable, the
number of events (e.g. disease progressions or relapses) must be
high enough. For each variable investigated, at least 10 events are
required [36]. If the number of events is small, only a few
exploratory variables can be investigated simultaneously [53]. In
the present study there were only 28 cases of disease progressions
or relapses (Table 2). This indicates that a maximum of two
variables could be included in a multivariate Cox regression
model.
In this study, the benefit of complete tumor resection and other
treatment-related factors for progression-free survival was not
investigated, because these variables were mostly unknown at the
beginning of survival time (i.e., at diagnosis). To investigate a
variable that is still elusive at the beginning of survival time or that
changes over time, a time-dependent Cox regression must be used.
For example, if the authors wish to know whether cancer patients’
cumulative dose of chemotherapy affects the length of time until
the tumor progresses, they cannot stipulate the cumulative dose as
a known quantity at the outset. Patients who survive longer will
generally receive a higher total dose. However, this high
cumulative dose is not the cause of longer disease control. To
allow for this, the cumulative dose must be included in a Cox
regression as a time-dependent variable. Time-dependent Cox
regression is a procedure that requires particularly detailed
information about the starting date of therapy, which is generally
not provided by case series/reports extracted from literature.
[14,53].
Limitations inherent to the concept of IPD meta-analyses
In addition, several limitations of this study are inherently in the
concept of individual patient data (ITP) meta-analyses. First, there
certainly was a selection bias, because the cases reported might
have been published because of their rare or uncommon
presentation and outcomes. Second, the data were gathered from
different institutions during a relatively long period of time, and
significant advances may have simultaneously occurred in
diagnostic and therapeutic approaches. Last but not least, not all
data assessed were available for every patient, which further
restricts the number of variables assessable in a multivariate model
[33].
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Conclusions
The clinical understanding of the three new members of the
family of glioneuronal tumors - PGNT, RGNT and GNTNI - is
currently in evolution. The present meta-analysis will hopefully
contribute to a narrower diagnostic, therapeutic, and prognostic
profile. However, the available data do not provide a solid basis to
define the optimum treatment approach. It is proposed to establish
a central register.
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